cardiovascular

FDA Panel Scrutinizing Diabetes Drug Avandia

On Tuesday, the FDA will convene a panel of experts to discuss GlaxoSmithKline's type II diabetes drug Avandia. Once a blockbuster, sales of the drug have dropped by more than half since studies suggested it significantly increases risk for serious heart problems.

Avandia Linked to Heart Attacks in Two New Studies

GlaxoSmithKline's diabetes drug Avandia once again captured headlines Monday morning after two new studies linked it to heart attacks and other cardiovascular complications. The authors of the studies say the results should prompt the FDA to pull the drug from the market.

Dialysis Firm DaVita 'Nervous' About Reform

While DaVita says health reform would allow the dialysis-center operator to offer more integrated care, it could hurt business if Medicare recipients become an even bigger part of its patient load. CEO Kent Thiry reviews the pros and cons of reform.